Advertisement
Kinnate Biopharma Inc. (KNTE)
Company Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States.
The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program.
The company was incorporated in 2018 and is headquartered in San Francisco, California.
Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.

Country | United States |
IPO Date | Dec 3, 2020 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 84 |
CEO | Nima Farzan M.B.A. |
Advertisement
Contact Details
Address: 103 Montgomery Street San Francisco, California United States | |
Website | https://www.kinnate.com |
Stock Details
Ticker Symbol | KNTE |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001797768 |
CUSIP Number | 49705R105 |
ISIN Number | US49705R1059 |
Employer ID | 82-4566526 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Nima Farzan M.B.A. | President, Chief Executive Officer & Director |
Mark A. Meltz | Chief Operating Officer, General Counsel, Treasurer & Secretary |
Neha Krishnamohan | Chief Financial Officer, Principal Accounting Officer and Executive Vice President of Corporate Development |
Dr. Richard Thomas Williams MBBS, Ph.D. | Chief Medical Officer |
Dr. Robert Kania Ph.D. | Senior Vice President of Research |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Apr 17, 2024 | 15-12G | Filing |
Apr 05, 2024 | 4 | Filing |
Apr 05, 2024 | 4 | Filing |
Apr 05, 2024 | 4 | Filing |
Apr 05, 2024 | 4 | Filing |
Apr 05, 2024 | 4 | Filing |
Apr 05, 2024 | 4 | Filing |
Apr 05, 2024 | 4 | Filing |
Apr 05, 2024 | 4 | Filing |